Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at Cantor Fitzgerald cut their FY2017 earnings per share estimates for shares of Aldeyra Therapeutics in a research note issued on Sunday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings of ($1.34) per share for the year, down from their previous forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating and a $22.00 target price on the stock.
A number of other equities research analysts have also weighed in on the company. Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “buy” rating and set a $6.75 price objective on the stock in a research report on Tuesday. ValuEngine lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reaffirmed an “outperform” rating and set a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.29.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) traded down $0.10 during mid-day trading on Wednesday, reaching $6.10. The company had a trading volume of 85,100 shares, compared to its average volume of 297,303. Aldeyra Therapeutics has a twelve month low of $3.80 and a twelve month high of $11.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09.
In related news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was purchased at an average cost of $7.25 per share, with a total value of $1,450,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 28.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. grew its holdings in Aldeyra Therapeutics by 31.0% during the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares during the period. Virtu KCG Holdings LLC bought a new position in Aldeyra Therapeutics during the second quarter valued at $104,000. Perceptive Advisors LLC grew its holdings in Aldeyra Therapeutics by 6.9% during the third quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after purchasing an additional 200,000 shares during the period. Bank of New York Mellon Corp bought a new position in Aldeyra Therapeutics during the third quarter valued at $134,000. Finally, Vanguard Group Inc. grew its holdings in Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares during the period. 40.34% of the stock is owned by institutional investors.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.